Ovarian Cancer: Can Repurposed Drugs Work Better Together? Clara Simón

https://www.medscape.com/viewarticle/ovarian-cancer-can-repurposed-drugs-work-better-together-2026a1000nre?src= Combination therapy with FDA-approved oxidative phosphorylation (OXPHOS) inhibitors and platelet-derived growth factor receptor (PDGFR) inhibitors may selectively target ovarian cancer stem cells and limit their enrichment by carcinoma-associated mesenchymal stem cells, according to a preclinical study published in NPJ Women’s Health. https://www.nature.com/articles/s44294-026-00134-x?utm_source=nature_etoc&utm_medium=email&utm_campaign=CONR_44294_AWA1_GL_DTEC_054CI_TOC-260601&utm_content=20260601